Related Experiment Videos
Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects
Jaume Sastre-Garriga1, Deborah Pareto2, Àlex Rovira2
1Department of Neurology/Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain.
Neuroimaging Clinics of North America
|April 11, 2017
Summary
Neuroimaging in multiple sclerosis (MS) shows brain atrophy linked to neurodegeneration. More research is needed to use brain volume measurements as biomarkers for patient care and treatment monitoring.
Area of Science:
- Neurology
- Neuroimaging
- Neurodegeneration
Background:
- Multiple sclerosis (MS) involves both inflammation and neurodegeneration.
- Magnetic Resonance (MR) imaging has been crucial in understanding MS neurodegeneration.
- Current evidence is insufficient to support MR imaging-measured brain atrophy as a routine biomarker in MS patient care.
Purpose of the Study:
- To discuss the prognostic value of brain volume measurements in MS.
- To explore the potential role of brain atrophy in monitoring treatment response in MS patients.
Main Methods:
- Review of existing literature on MR imaging and brain atrophy in MS.
- Discussion of the utility of brain volume measurements as biomarkers.
Main Results:
- MR imaging has significantly advanced the understanding of neurodegeneration in MS.
- Brain atrophy measurements show prognostic potential.
- Further validation is required for routine clinical use in monitoring treatment.
Conclusions:
- Brain atrophy is a key feature of neurodegeneration in MS.
- Brain volume measurements hold promise for predicting MS progression.
- The role of these measurements in monitoring treatment efficacy requires further investigation.